Stem definition | Drug id | CAS RN |
---|---|---|
oxytocin derivatives | 2042 | 50-56-6 |
Dose | Unit | Route |
---|---|---|
15 | U | N |
200 | U | O |
15 | U | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
April 17, 1980 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 716.30 | 34.41 | 289 | 3823 | 107923 | 46574027 |
Postpartum haemorrhage | 475.68 | 34.41 | 89 | 4023 | 1708 | 46680242 |
Maternal exposure during pregnancy | 404.96 | 34.41 | 191 | 3921 | 102358 | 46579592 |
Caesarean section | 202.83 | 34.41 | 70 | 4042 | 16533 | 46665417 |
Uterine atony | 199.10 | 34.41 | 30 | 4082 | 135 | 46681815 |
Maternal exposure during delivery | 194.26 | 34.41 | 37 | 4075 | 779 | 46681171 |
Hypotension | 181.39 | 34.41 | 155 | 3957 | 232434 | 46449516 |
Uterine rupture | 120.44 | 34.41 | 26 | 4086 | 1038 | 46680912 |
Premature delivery | 108.12 | 34.41 | 48 | 4064 | 22021 | 46659929 |
Foetal exposure during pregnancy | 104.66 | 34.41 | 52 | 4060 | 30695 | 46651255 |
Pre-eclampsia | 90.95 | 34.41 | 32 | 4080 | 7962 | 46673988 |
Normal newborn | 87.77 | 34.41 | 29 | 4083 | 5972 | 46675978 |
Electrocardiogram ST segment depression | 87.11 | 34.41 | 24 | 4088 | 2669 | 46679281 |
Anaphylactic reaction | 75.78 | 34.41 | 51 | 4061 | 53061 | 46628889 |
Drug ineffective | 74.56 | 34.41 | 175 | 3937 | 677663 | 46004287 |
Anaphylactoid syndrome of pregnancy | 69.78 | 34.41 | 10 | 4102 | 29 | 46681921 |
Placenta accreta | 61.37 | 34.41 | 11 | 4101 | 163 | 46681787 |
Amniotic cavity infection | 59.74 | 34.41 | 15 | 4097 | 1163 | 46680787 |
Stillbirth | 55.30 | 34.41 | 21 | 4091 | 6470 | 46675480 |
Low birth weight baby | 55.18 | 34.41 | 20 | 4092 | 5414 | 46676536 |
Premature baby | 53.91 | 34.41 | 28 | 4084 | 18084 | 46663866 |
Bradycardia foetal | 52.91 | 34.41 | 11 | 4101 | 365 | 46681585 |
Premature rupture of membranes | 51.42 | 34.41 | 18 | 4094 | 4405 | 46677545 |
Uterine haemorrhage | 50.96 | 34.41 | 17 | 4095 | 3600 | 46678350 |
Retained placenta or membranes | 49.95 | 34.41 | 10 | 4102 | 274 | 46681676 |
Pulmonary oedema | 47.70 | 34.41 | 38 | 4074 | 51067 | 46630883 |
Vascular resistance systemic decreased | 45.53 | 34.41 | 8 | 4104 | 105 | 46681845 |
Tachycardia | 44.25 | 34.41 | 49 | 4063 | 99573 | 46582377 |
Cardiac output increased | 43.65 | 34.41 | 8 | 4104 | 135 | 46681815 |
Mean arterial pressure decreased | 42.75 | 34.41 | 8 | 4104 | 152 | 46681798 |
Endometritis | 42.44 | 34.41 | 11 | 4101 | 968 | 46680982 |
Gestational diabetes | 39.53 | 34.41 | 17 | 4095 | 7202 | 46674748 |
Small for dates baby | 39.23 | 34.41 | 14 | 4098 | 3623 | 46678327 |
Disseminated intravascular coagulation | 39.00 | 34.41 | 23 | 4089 | 18982 | 46662968 |
Gestational hypertension | 37.97 | 34.41 | 12 | 4100 | 2143 | 46679807 |
Vaginal haemorrhage | 37.46 | 34.41 | 25 | 4087 | 25579 | 46656371 |
Hypothermia | 36.72 | 34.41 | 19 | 4093 | 12164 | 46669786 |
Uterine hypertonus | 36.22 | 34.41 | 7 | 4105 | 159 | 46681791 |
Stroke volume increased | 36.20 | 34.41 | 5 | 4107 | 10 | 46681940 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal exposure during pregnancy | 346.90 | 111.39 | 81 | 296 | 36790 | 29915311 |
Premature baby | 140.72 | 111.39 | 34 | 343 | 16657 | 29935444 |
Source | Code | Description |
---|---|---|
ATC | G02AC01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids and oxytocin incl. analogues, in combination |
ATC | H01BB02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Oxytocin and analogues |
FDA CS | M0015703 | Oxytocin |
FDA PE | N0000009705 | Increased Uterine Smooth Muscle Contraction or Tone |
CHEBI has role | CHEBI:35620 | vasodilator |
CHEBI has role | CHEBI:36063 | oxytocic |
FDA EPC | N0000175828 | Oxytocic |
MeSH PA | D010120 | Oxytocics |
MeSH PA | D012102 | Reproductive Control Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Postpartum hemorrhage | indication | 47821001 | |
Incomplete miscarriage | indication | 156072005 | |
Induction of labor | indication | 236958009 | |
Pregnancy with abortive outcome | indication | 363681007 | |
Placental Reserve Studies | off-label use | ||
Multiple pregnancy | contraindication | 16356006 | |
Grand multipara | contraindication | 18656007 | |
Placenta previa | contraindication | 36813001 | DOID:11060 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Fetal distress | contraindication | 130955003 | |
Deliveries by cesarean | contraindication | 200144004 | |
Finding of malposition of fetus | contraindication | 289365005 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.65 | acidic |
pKa2 | 12.47 | acidic |
pKa3 | 12.94 | acidic |
pKa4 | 13.18 | acidic |
pKa5 | 13.47 | acidic |
pKa6 | 13.7 | acidic |
pKa7 | 13.89 | acidic |
pKa8 | 6.4 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Oxytocin receptor | GPCR | AGONIST | Ki | 9.10 | CHEMBL | CHEMBL | |||
Vasopressin V2 receptor | GPCR | EC50 | 6.10 | WOMBAT-PK | |||||
Vasopressin V1b receptor | GPCR | EC50 | 6.35 | WOMBAT-PK | |||||
Vasopressin V1a receptor | GPCR | EC50 | 6.91 | WOMBAT-PK | |||||
Oxytocin-neurophysin 1 | Secreted | WOMBAT-PK | |||||||
Vasopressin V2 receptor | GPCR | Ki | 7.21 | CHEMBL | |||||
Oxytocin receptor | GPCR | Ki | 9.05 | CHEMBL | |||||
Vasopressin V1a receptor | GPCR | AGONIST | Ki | 6.10 | IUPHAR |
ID | Source |
---|---|
4018039 | VUID |
N0000146381 | NUI |
D00089 | KEGG_DRUG |
4018039 | VANDF |
C0030095 | UMLSCUI |
CHEBI:7872 | CHEBI |
CHEMBL395429 | ChEMBL_ID |
D010121 | MESH_DESCRIPTOR_UI |
DB00107 | DRUGBANK_ID |
2174 | IUPHAR_LIGAND_ID |
1480 | INN_ID |
1JQS135EYN | UNII |
439302 | PUBCHEM_CID |
7824 | RXNORM |
4537 | MMSL |
5223 | MMSL |
d00584 | MMSL |
001307 | NDDF |
112115002 | SNOMEDCT_US |
12369008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9742 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9743 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6114 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6115 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-130 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-048 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-051 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-054 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-055 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 15 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-105 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-170 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-233 | INJECTION, SOLUTION | 20 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-234 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-9584 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |